Previous 10 | Next 10 |
Summary Stryker posted impressive top-line growth in Q4, driven by mid-teens growth in the MedSurg & Neuro operations. Margins remain a drag as Stryker has struggled to offset higher input costs. I see upside potential in FY'23 revenue, with Stryker launching several significant...
Summary The January market rally saw small caps leading the way, followed by mid-caps. The SMID Moat Index benefited most from its exposure to consumer discretionary, industrials, and information technology companies. Stock selection within smaller cap stocks, though less exposure, ...
Summary U.S. stock market indices started off the year notably strong as investors were quick to put a bruising 2022 in the rearview. The Moat Index’s outperformance in January, relative to the S&P 500 Index, was driven primarily by strong stock selection. The Morningstar...
Summary Zimmer Biomet posted promising fourth quarter results, with revenue beats down the line and improved gross margin. Share gains in knees is very encouraging, particularly with Rosa pull-through still in its early stages, but I want to see better results in hips. The deal for ...
Summary ZBH posted strong revenue growth in 4Q22 with organic growth of 10% and an earnings per share of $1.88. The Large Joints segment, particularly Knees, performed exceptionally well. There should be increased volume in the Ortho market as we get past the covid impact and the labour...
Zimmer Biomet Holdings Inc. (ZBH) Q4 2022 Earnings Conference Call February 3, 2023 8:30 am ET Company Participants Bryan Hanson - President, Chief Executive Officer Suketu Upadhyay - Executive Vice President, Chief Financial Officer Ivan Tornos - Chief Operating Offic...
Zimmer Biomet press release ( NYSE: ZBH ): Q4 Non-GAAP EPS of $1.88 beats by $0.05 . Revenue of $1.83B (+3.4% Y/Y) beats by $70M . For FY2023, the company expects revenue growth of 1.5% to 3.5% vs. consensus growth of 1.9%; Adjusted EPS of $6.95 to $7.15 vs. consensus ...
Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results PR Newswire Fourth quarter net sales from continuing operations of $1.825 billion increased 2.7% and 8.3% on a constant currency 1 basis Fourth quarter diluted loss per share from continuin...
Zimmer Biomet ( NYSE: ZBH ) is scheduled to announce Q4 earnings results on Friday, February 3rd, before market open. The consensus EPS Estimate is $1.83 (-6.2% Y/Y) and the consensus Revenue Estimate is $1.76B (-13.7% Y/Y). Over the last 2 years, ZBH has beaten EPS estimate...
Summary ResMed continues to be a leading company in the industry, with multiple growth drivers ahead of its 2025 goals. But the outlook for ResMed doesn't look good, with YoY figures slowing and dividend payments possibly being interrupted. This has called its high valuation multipl...
News, Short Squeeze, Breakout and More Instantly...
Zimmer Biomet Holdings Inc. Company Name:
ZBH Stock Symbol:
NYSE Market:
Zimmer Biomet Holdings Inc. Website:
2024-07-15 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2024 Financial Results PR Newswire WARSAW, Ind. , July 8, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will ...
Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors PR Newswire WARSAW, Ind. , June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdika...